Dlin-MC3-DMA: Ionizable Cationic Liposome for Potent Lipid Nanoparticle siRNA Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is an ionizable cationic liposome lipid that enables efficient in vivo delivery of siRNA and mRNA through lipid nanoparticle (LNP) formulations [Wang et al., 2022]. Its pH-sensitive charge properties support endosomal escape by transitioning from neutral at physiological pH to cationic at acidic endosomal pH. Dlin-MC3-DMA achieves gene silencing at doses as low as 0.005 mg/kg in mice, significantly surpassing its precursor DLin-DMA [APExBIO Product Page]. The lipid is insoluble in water and DMSO, but highly soluble in ethanol, and is a key ingredient in next-generation mRNA vaccine and cancer immunochemotherapy LNPs. Machine learning models have validated DLin-MC3-DMA as a gold standard for LNP design, outperforming other ionizable lipids in preclinical benchmarking [Wang et al., 2022].

Biological Rationale

Lipid nanoparticles (LNPs) are essential carriers for nucleic acid-based therapeutics, including siRNA and mRNA vaccines [Wang et al., 2022]. Ionizable cationic liposomes like Dlin-MC3-DMA facilitate encapsulation and delivery of negatively charged nucleic acids. At physiological pH (~7.4), Dlin-MC3-DMA is predominantly neutral, reducing systemic toxicity and non-specific interactions [APExBIO]. Upon endocytosis, acidification in the endosome (pH 5.0–6.5) leads to protonation of the lipid's tertiary amine, converting it to a cationic state. This transition enables strong electrostatic interactions with the endosomal membrane, promoting endosomal disruption and release of the payload into the cytoplasm [Related Article: Endosomal Escape]. Dlin-MC3-DMA's structure also enhances its compatibility with other LNP components such as DSPC, cholesterol, and PEGylated lipids, supporting stable nanoparticle assembly and efficient in vivo biodistribution.

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Dlin-MC3-DMA acts as the principal ionizable lipid within LNPs designed for nucleic acid delivery. Its unique (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate structure features a tertiary amine group that is selectively protonated at acidic pH. The mechanism comprises several sequential steps:

• Encapsulation: At mildly acidic formulation conditions (pH 4.0–5.5), Dlin-MC3-DMA is fully protonated, maximizing electrostatic interactions with siRNA or mRNA and enhancing encapsulation efficiency (Wang et al., 2022).
• Circulation: On intravenous administration, the LNPs encounter neutral physiological pH, rendering Dlin-MC3-DMA mostly neutral, minimizing interaction with plasma proteins and reducing off-target toxicity (APExBIO).
• Endocytosis and Endosomal Escape: Cellular uptake occurs via endocytosis. Acidification in endosomes re-protonates Dlin-MC3-DMA, which facilitates disruption of the endosomal membrane by promoting non-lamellar phase transitions and membrane fusion. This enables efficient cytoplasmic release of nucleic acids (Endosomal Escape Article).
• Gene Silencing: Released siRNA or mRNA engages the cellular machinery, resulting in target gene knockdown or protein expression as intended (Wang et al., 2022).

This pH-dependent ionization and membrane activity are critical to the superior performance of Dlin-MC3-DMA in LNP-based gene therapies.

Evidence & Benchmarks

• Dlin-MC3-DMA-containing LNPs achieved potent hepatic gene silencing with an ED₅₀ of 0.005 mg/kg for transthyretin (TTR) siRNA in mice (https://doi.org/10.1016/j.apsb.2021.11.021).
• In non-human primates, Dlin-MC3-DMA LNPs produced effective TTR gene knockdown at 0.03 mg/kg (https://doi.org/10.1016/j.apsb.2021.11.021).
• Compared to its predecessor DLin-DMA, Dlin-MC3-DMA demonstrated ~1000-fold greater gene silencing potency in vivo (https://doi.org/10.1016/j.apsb.2021.11.021).
• LNPs formulated with Dlin-MC3-DMA outperformed SM-102 in mRNA delivery efficiency in murine models (https://doi.org/10.1016/j.apsb.2021.11.021).
• Machine learning models (LightGBM) validated the high efficacy of Dlin-MC3-DMA as an ionizable lipid for mRNA LNPs, achieving R² > 0.87 in predicting formulation potency (https://doi.org/10.1016/j.apsb.2021.11.021).
• Dlin-MC3-DMA LNPs are a benchmark component in COVID-19 mRNA vaccine research, owing to their favorable pharmacokinetics and safety profile (https://doi.org/10.1016/j.apsb.2021.11.021).

Applications, Limits & Misconceptions

Dlin-MC3-DMA is a preferred ionizable cationic liposome for:

• Hepatic gene silencing via siRNA delivery (e.g., for TTR, Factor VII).
• mRNA vaccine formulation, including COVID-19 and cancer immunochemotherapy applications.
• Translational studies requiring efficient endosomal escape and low systemic toxicity.
• High-throughput formulation screening, including AI-driven optimization [This article provides detailed molecular-ML integration, expanding on the current article's mechanistic focus.].

For a deeper dive into immunomodulatory and neuroinflammatory LNP systems, see this review, which covers Dlin-MC3-DMA's impact beyond hepatic targets. Our present article updates practical workflow integration parameters not found in previous reviews.

Common Pitfalls or Misconceptions

• Not a Universal Solvent: Dlin-MC3-DMA is insoluble in water and DMSO; it is only soluble in ethanol (≥152.6 mg/mL) (APExBIO).
• Limited to LNPs: Its efficacy is documented specifically in LNP systems, not as a stand-alone transfection reagent.
• Not Effective at Neutral pH Alone: Endosomal escape activity depends on acidic pH-induced protonation.
• Formulation Instability if Improperly Stored: Solutions degrade rapidly at >-20°C; long-term storage at -20°C or below is mandatory.
• No Direct Activity Against DNA: Optimized for siRNA/mRNA, not for DNA or protein delivery.

Workflow Integration & Parameters

For effective use of Dlin-MC3-DMA, follow these workflow recommendations:

• Formulation Ratio: Typical LNP ratios are ionizable lipid:DSPC:cholesterol:PEG-lipid = 50:10:38.5:1.5 (mol%) [Wang et al., 2022].
• Solubilization: Dissolve Dlin-MC3-DMA in ethanol (≥152.6 mg/mL); avoid aqueous or DMSO-based dissolution.
• Mixing: Use microfluidic mixing at pH 4.0–5.5 for >90% encapsulation efficiency.
• Storage: Store the neat lipid at -20°C or below. Prepare fresh solutions for immediate use to prevent degradation (APExBIO).
• Validation: Confirm LNP size (typically 80–120 nm) and encapsulation efficiency via DLS and RiboGreen assay, respectively.

For practical optimization and troubleshooting, see this methods article, which our current review extends with new benchmarking data.

Conclusion & Outlook

Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is a leading ionizable cationic liposome for lipid nanoparticle siRNA delivery and mRNA vaccine formulation. Its pH-responsive properties enable highly efficient endosomal escape, low toxicity, and benchmarked in vivo gene silencing at ultra-low doses. Advanced machine learning models now validate its status as a gold standard for LNP design, facilitating rapid, cost-effective optimization for both basic research and clinical translation [Wang et al., 2022]. For product details or batch-specific documentation, consult the APExBIO Dlin-MC3-DMA (A8791) page.